hyperlipidemia
Showing 1 - 25 of 337
Hyperlipidemia Trial in Beijing (JS401, Placebo)
Recruiting
- Hyperlipidemia
- JS401
- Placebo
-
Beijing, Beijing, ChinaPeking University Third Hospital
Sep 15, 2023
Cardiometabolic Disease, Hyperlipidemia Trial in Beijing (Telehealth integrated care, Conventional health care)
Recruiting
- Cardiometabolic Disease
- Hyperlipidemia
- Telehealth integrated care
- Conventional health care
-
Beijing, Beijing, ChinaPeking University Third Hospital
Sep 1, 2023
Hyperlipidemia Trial in Leuven (Cholesfytol NG®) supplement)
Completed
- Hyperlipidemia
- Cholesfytol NG®) supplement
-
Leuven, BelgiumCliniques universitaires St-Luc and Institut de Recherche Expéri
Aug 18, 2023
Hyperlipidemia, Hyperglycemia, Type 2 Diabetes Trial in Taipei (Adlay with white rice, white rice)
Recruiting
- Hyperlipidemia
- +2 more
- Adlay with white rice
- white rice
-
Taipei, TaiwanNational Taiwan University Hospital
Aug 17, 2023
Lipodystrophy, Diabetes, Hyperlipidemia Trial run by the NIDDK (Metreleptin)
Recruiting
- Lipodystrophy
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Diabetes, Lipodystrophy, Hyperlipidemia Trial run by the NIDDK (Metreleptin)
Active, not recruiting
- Diabetes
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 21, 2023
Lipoprotein Metabolism in Normal Volunteers and High Levels of
Completed
- Hypolipoproteinemia
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Hyperlipidemia Trial in Guangzhou (SHR-1209, Placebo)
Completed
- Hyperlipidemia
- SHR-1209
- Placebo
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital ,The Second Affiliated Hospital of
Nov 29, 2022
Hyperlipidemia, Mixed Dyslipidemia Trial in Denver (Evolocumab)
Completed
- Hyperlipidemia
- Mixed Dyslipidemia
- Evolocumab
-
Denver, ColoradoResearch Site
Nov 3, 2022
Non-surgical Periodontal Therapy on Severe Periodontitis and
Recruiting
- Periodontitis Chronic Generalized Severe
- +5 more
- non-surgical periodontal therapy
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Sep 17, 2022
Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot
Recruiting
- Hyperlipidemia
- Pregnancy
-
New York, New YorkMount Sinai OBGYN Faculty Practice Associates
Sep 9, 2022
Cardiovascular Disease, Hypertension, Diabetes Trial in Boston, Philadelphia, Charleston (Unmet Need Screening, Unmet Need
Recruiting
- Cardiovascular Disease
- +3 more
- Unmet Need Screening
- +2 more
-
Boston, Massachusetts
- +2 more
Aug 12, 2022
Metabolic Syndrome and Gen-polymorphs Influence on Weightloss
Completed
- Childhood Obesity
- +4 more
- Chronic care multidisciplinary intervention of childhood obesity
-
Holbaek, DenmarkThe Children's Obesity Clinic, Paediatric Department, University
Jul 15, 2022
Coronary Artery Disease, Bypass Graft Stenosis, Dyslipidemias Trial (Computed tomography coronary angiogram)
Not yet recruiting
- Coronary Artery Disease
- +7 more
- Computed tomography coronary angiogram
- (no location specified)
May 24, 2022
Hypercholesterolemia, Hyperlipidemia Trial in Beijing (SHR-1209 ;)
Active, not recruiting
- Hypercholesterolemia
- Hyperlipidemia
- SHR-1209 ;placebo
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital, Capital Medical University
May 23, 2022
Hyperlipidemia Trial in Shanghai (DC371739, Placebo)
Completed
- Hyperlipidemia
- DC371739
- Placebo
-
Shanghai, Shanghai, ChinaShanghai Xu hui Central Hospital
Mar 15, 2022
Hyperlipidemia Trial in Hangzhou, Shanghai (AK102, Placebo)
Recruiting
- Hyperlipidemia
- AK102
- Placebo
-
Hangzhou, Zhejiang, China
- +1 more
Feb 18, 2022
Hyperlipidemia Trial in Nanchang (AK102, Placebo)
Recruiting
- Hyperlipidemia
- AK102
- Placebo
-
Nanchang, Jiangxi, ChinaThe Third Hospital of Nanchang
Feb 15, 2022
Hyperlipidemia Trial in Beijing (AK102, Placebo)
Recruiting
- Hyperlipidemia
- AK102
- Placebo
-
Beijing, ChinaPeking University First Hospital
Feb 15, 2022
Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters:
Completed
- Hyperlipidemia
- Omega-3 fatty acid ethyl esters
- Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
-
Osaka, Japan
- +1 more
Dec 2, 2021
Hypercholesterolemia, Hyperlipidemia Trial (Vytorin + Niaspan, Vytorin, Niaspan)
Completed
- Hypercholesterolemia
- Hyperlipidemia
- Vytorin + Niaspan
- +2 more
- (no location specified)
Feb 7, 2022